Previous Article | Next Article 
Molecular and Cellular Biology, September 1998, p. 5414-5424, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Stress-Induced Fas Ligand Expression in T Cells Is
Mediated through a MEK Kinase 1-Regulated Response Element in the
Fas Ligand Promoter
Mary
Faris,1
Kevin M.
Latinis,2
Stephan J.
Kempiak,1
Gary A.
Koretzky,2 and
Andre
Nel1,*
Division of Clinical Immunology and Allergy,
Department of Medicine, UCLA School of Medicine, Los Angeles,
California 90095,1 and
Department of
Internal Medicine and Interdisciplinary Graduate Program in
Immunology, University of Iowa, Iowa City, Iowa
522422
Received 20 February 1998/Returned for modification 16 April
1998/Accepted 22 June 1998
 |
ABSTRACT |
T lymphocytes undergo apoptosis in response to a variety of
stimuli, including exposure to UV radiation and
-irradiation. While
the mechanism by which stress stimuli induce apoptosis is not well
understood, we have previously shown that the induction of Fas ligand
(FasL) gene expression by environmental stress stimuli is dependent on
c-Jun N-terminal kinase (JNK) activation. Using inducible
dominant-active (DA) JNK kinase kinase (MEKK1) expression in Jurkat
cells, we map a specific MEKK1-regulated response element to positions
338 to
316 of the Fas ligand (FasL) promoter. Mutation of that
response element abrogated MEKK1-mediated FasL promoter activation and
interfered in stress-induced activation of that promoter. Using
electrophoretic mobility shift assays, we demonstrate that activator
protein 1 (AP-1) binding proteins, namely, activating transcription
factor 2 (ATF2) and c-Jun, bind to the MEKK1 response element.
Transient transfection of interfering c-Jun and ATF2 mutants, which
lack the consensus JNK phosphorylation sites, abrogated the
transcriptional activation of the FasL promoter, demonstrating the
involvement of these transcription factors in the regulation of the
FasL promoter. Taken together, our data indicate that MEKK1 and
transcription factors regulated by the JNK pathway play a role in
committing lymphocytes to undergo apoptosis by inducing FasL expression
via a novel response element in the promoter of that gene.
 |
INTRODUCTION |
In response to antigenic challenge,
lymphocytes become activated, secrete cytokines, and proliferate. Yet
to maintain homeostasis, once the antigen has been cleared, activated
lymphocytes are removed by a process of apoptosis (6, 45,
52). While recent studies have provided considerable insight into
the role of intracellular signaling pathways utilized by death-inducing
receptors such as Fas and tumor necrosis factor alpha (TNF-
) type 1 receptor (TNFR1) (1, 13, 22, 23, 36, 45, 48), we still lack
a clear understanding of the molecular pathways which regulate the
commitment of lymphocytes to die. A number of signaling pathways and
nuclear transcription factors play a role in regulating apoptosis
(5, 14, 17, 40, 48, 54, 58). However, relatively little is
known about the signaling pathways and transcription factors which
tightly regulate the expression of Fas ligand (FasL). We have recently
shown that T-cell receptor (TCR)-mediated signals leading to activation
of nuclear factor of activated T cells (NF-AT) response elements in the
FasL promoter are important for FasL expression in lymphocytes
(28). Additionally, we have shown that FasL expression plays
a role in stress-mediated apoptosis in T cells (14). In
contrast to FasL inducing signals delivered through the TCR, stress
signals leading to FasL expression, such as those resulting from
exposure to UV radiation (UVR),
-irradiation, or protein synthesis
inhibitors, appear to be mediated via activation of the c-Jun
N-terminal kinase (JNK) cascade (14).
The role of the JNK cascade in cellular apoptosis has been
controversial, with evidence reported for pro- and antiapoptotic effects. Data which favor a proapoptotic role include (i) induction of
apoptosis by dominant-active (DA) JNK kinase kinase (MEKK1) in Jurkat
cells, fibroblasts, and PC12 cells (14, 26, 58), (ii)
interference in apoptosis induction by ceramide or growth factor
withdrawal by dominant-negative (DN) JNK cascade components, e.g.,
DN-SAP/ERK kinase (SEK1) or DN-MEKK1 (18, 55), (iii) induction of apoptosis in T lymphocytes during prolonged activation of
the JNK cascade, e.g.,
-irradiation and DA-MEKK1 expression (7,
8, 14), and (iv) interference in apoptosis induction and JNK
activation by a DN version of the Daxx effector, which interacts with
the intracellular death domain of the Fas receptor (27a). In
contrast, evidence against the involvement of the JNK cascade in
promoting apoptosis includes the proapoptotic effect of homozygous SEK1
knockout in murine thymocytes (38). Moreover, TNFR1 still
induces apoptosis when its JNK-inducing component, tumor necrosis
factor receptor-associated factor (TRAF2), is mutagenized so that it no
longer activates JNK (31). It has been suggested that JNK
activation may follow activation of the caspase cascade (4, 29,
31, 37). These data suggest, therefore, that the JNK cascade may
be redundant or may occur secondary to cellular damage associated with
apoptosis. This notion explains why a cell nucleus and accompanying
nuclear response elements are not obligatory requirements for the
induction of apoptosis (2, 29, 50).
Our recent studies have shed new light on the paradoxical role of the
JNK cascade in apoptosis. While DN-MEKK1 failed to interfere with
TNFR1-induced apoptosis, prolonged activation of the JNK cascade by
stress stimuli or DA-MEKK1 expression in Jurkat cells induced apoptosis
through FasL expression (7, 8, 14, 31). This process was
reversed by Fas-Fc fusion protein, which interferes in the Fas-FasL
interaction (14). Moreover, several groups have shown that
there is a decreased rate of apoptosis in MRL-lpr/lpr mice during
exposure to environmental stress, e.g., UVR (9, 43). These
findings have led us to propose that, instead of a direct role in the
delivery of the death signal, the JNK cascade commits T cells to
apoptosis through FasL expression. FasL expression may, therefore, act
as a fail-safe mechanism to remove T cells which have been damaged by
noxious stimuli. Further, this mechanism appears to operate only when
there is prolonged JNK activation; evanescent JNK activation by
TCR-CD28 coligation fails to induce apoptosis (14). We
propose that TCR-mediated signals which regulate FasL expression differ
from stress-induced signals.
In order to clarify the role of the JNK cascade in FasL expression, we
asked whether there is a MEKK1 response element in the promoter of that
gene. By transfecting 5' serially deleted FasL promoter constructs into
Jurkat cells with tetracycline-inducible DA-MEKK1 expression, we show
that DA-MEKK1 expression induces the transcriptional activation of the
486 FasL promoter through a specific MEKK1 responsive element which
was mapped between positions
336 and
318 upstream from the
transcriptional start site. Mutation of that site abrogated FasL
promoter activation by the JNK cascade and stress stimuli. Using
electrophoretic mobility shift assays (EMSA), we find that activator
protein 1 (AP-1) proteins, including activating transcription factor 2 (ATF2) and c-Jun, bind to the specific response element. Further, by
transient transfection, we demonstrate that these proteins are involved
in the transcriptional regulation of the FasL promoter.
 |
MATERIALS AND METHODS |
Reagents.
Anti-MEKK1 monoclonal antibody (MAb) as well as
antibodies for supershift analysis, i.e., anti-c-Jun, anti-Fos, and
anti-ATF2, were from Santa Cruz Biotechnology (Santa Cruz, Calif.). The
horseradish peroxidase (HRP)-conjugated protein A was purchased from
Amersham (Arlington Heights, Ill.). The FasL antibody was from
PharMingen (San Diego, Calif.). The glutathione
S-transferase (GST)-c-Jun construct was generously provided
by J. Woodgett (Ontario Cancer Institute, Ontario, Canada). Phorbol
myristate acetate (PMA) and ionomycin were purchased from Sigma (St.
Louis, Mo.). The tetracycline-repressible system, including the
pUHD15.1 and pUHD10.3 vectors, was a kind gift from H. Bujard
(Heidelberg, Germany) (19). The pUHD15.1 plasmid encodes for
the tetracycline-controlled transactivator (tTA), and the pUHD10.3
plasmid contains a tTA-dependent promoter upstream of a multiple
cloning site (19). The cDNAs for DA-MEKK1 (MEKK
) and
DN-MEKK (MEKK
K432M) were a gift from G. Johnson (National Jewish
Center for Immunology and Research, Denver, Colo.) (33).
DA-MEKK1 and DN-MEKK1 were subcloned into the multiple cloning site of
pUHD10.3, respectively. DN JNK kinase (SEK1 and MKK4) was generously
provided by Leonard Zon (Harvard Medical School, Boston, Mass.).
FasL constructs.
The
486 FasL promoter construct,
consisting of the first 486 nucleotides upstream of the start site, has
been described previously (28). Briefly, the
486-bp
FasL reporter construct was created by cloning a
HindIII-flanked 486-bp PCR product derived
from genomic sequence upstream of the FasL translational start site
into the Luc-Link reporter plasmid. The truncation mutants were created by cloning a BamHI/HindIII-flanked (or
BglII/HindIII-flanked, for FasL
420)
PCR product derived from the above construct into the Luc-Link plasmid.
The reverse primer was the same as for the 486-bp product, while the
forward primers were as follows: for FasL
420,
CATAGATCTGAGCAGTTCACACTAACAGGGCT; for FasL
353,
CATGGATCCGCATAGCCTACTAACCTGTTTGGG; for FasL
335,
CATGGATCCTTTGGGTAGCACAGCGACAGCAA; for FasL
318, CAGGGATCCGCTCTGAGCTTCTTG; for FasL
258,
CAGGGATCCCAGCAACTGAGGCCTTGAAGGC; for FasL
132,
CATGGATCCCTCTATAAGAGAGATCCAGCTTGC; and for FasL
95, TACGGATCCAGCAGTCAGCAACAGGGTCCCG. The
369
construct was created by subcloning a
BamHI-HindIII fragment from
486 into
Luc-Link. The distal NF-AT binding site mutant and the
336/
318
mutant constructs were created by overlap extension PCR with the
following forward (F) and reverse (R) end primers: F,
5'-GAACAAGCTTAATGTATAAAAAAGCATGCAATTATAATTC-3'; R,
5'-ACATAAGCTTGGCAGCTGGTGAGTCAGGCCA-3'. The following primers were used to incorporate the appropriate mutations: for the FasL
NFAT mutant, F, 5'-GTGGGAATCAACTTCCAGG-3', and R,
5'-CCTGGAAGTTGATTCCCAC-3', and for the FasL
336/
318
mutant, F, 5'-GATTCAGATCTCTTTGAAGCAACTGAGGCCTTGAAGGCT-3', and R,
5'-TCAAAGAGATCTGAATCACAGGTTAGTAGGCTATGCTCACC-3'.
Sequences of all PCR-derived constructs were confirmed by
fluorescent automated sequencing (University of Iowa DNA facility, Iowa
City, Iowa).
The triplicated
336/
318 construct was synthesized by annealing the
following oligonucleotides containing overhanging XhoI compatible sites into a minimal interleukin 2 (IL-2) promoter luciferase construct: F,
5'-TCGAGTGTCGCTGTGCTACCCAAACAGTGTCGCTGTGCTACCCAAACAGTGTCGCTG TGCTACCCAAACAGC-3',
and R,
5'-TCGAGCTGTTTGGGTAGCACAGCGACACTGTTTGGGTAGCACAGCGACACTGTTTGGGTAGCACAGCGACAC-3'.
Transfection and generation of stable transfectants.
A
subclone of Jurkat cells, BMS2, was transfected by electroporation with
10 µg of pUHD15.1 plasmid as previously described (15). A
stable Jurkat tTA cell line was generated by selection in 2 mg of
G418/ml and cloning by limiting dilution as previously described
(15). Jurkat tTA cells were transfected with 30 µg of
pUHD10.3 encoding DA-MEKK1. Cells were selected in 270 µg of hygromycin/ml for 4 weeks prior to the start of experiments.
Luciferase assays.
A total of 107 DA-MEKK1 cells
were transiently transfected with 30 µg of FasL promoter-reporter
construct. Duplicate samples were pooled and grown in the presence or
absence of 0.1 µg of tetracycline/ml as indicated. The cells were
either left unstimulated or treated with a combination of 100 nM PMA
and 1 µg of ionomycin/ml for 7 h. The cells were washed and
lysed in luciferase buffer (Analytical Luminescence, Ann Arbor, Mich.),
and luciferase activity was measured by using 100 µg of protein in a
Monolight 2010 luminometer (Analytical Luminescence) (15).
Transfection efficiency was monitored by cotransfection of a
-galactosidase-encoding plasmid (CMV-
-Gal) and measurement of
relative
-galactosidase activity. The same approach was used for
transient transfection of Jurkat-tTA cells with DN-MEKK1 subcloned into
the pUHD10.3 vector.
EMSA.
EMSA was performed as previously described
(28). Briefly, the double-stranded oligonucleotide,
5'-TTGGGTAGCACAGCGA-3', corresponding to positions
336 to
318 of the FasL promoter, was end labeled with Klenow fragment in the
presence of [
-32P]dCTP (Dupont-NEN, Boston, Mass.).
Nuclear extracts were prepared from unstimulated cells, and cells were
treated with PMA plus ionomycin for 3 h as previously described
(25). Ten micrograms of nuclear extract was incubated with
12 ng of radiolabeled probe for 20 min at room temperature and
separated on 4.5% acrylamide gels. Gels were dried and
autoradiographed. For supershift analysis, nuclear extracts were
preincubated with 0.5 µg of each respective antibody for 20 min prior
to the binding reaction.
Western blot analysis.
Tetracycline was withdrawn for
24 h from aliquots of 107 Jurkat tTA cells transfected
with DA-MEKK1. The cells were washed and lysed as previously described
(14). Cell lysates (100 µg) were separated by sodium
dodecyl sulfate-10% polyacrylamide gel electrophoresis (SDS-10%
PAGE) and transferred to Immobilon-P membranes. The membranes were
probed with 0.2 µg of anti-MEKK1/ml, followed by a 1:3,000 dilution
of HRP-coupled protein A (14). The blots were developed by
enhanced chemiluminescence (ECL) according to the manufacturer's
instructions.
JNK kinase assays.
A total of 5 × 106
DA-MEKK1 Jurkat cells were grown in the presence (tet+) or
absence (tet
) of tetracycline for 24 h. The cells
were left untreated or were stimulated with a combination of 100 nM PMA
and 1 µg of ionomycin/ml for 10 min. The cells were lysed, the
supernatants were incubated with recombinant GST-c-Jun(1-79) bound to
glutathione-coupled beads, and the complex was washed extensively in
lysis buffer. Kinase assays were performed as previously described
(15). The fold increase in kinase activity was determined by
PhosphorImager analysis.
Measurement of apoptosis.
Trypan blue exclusion was used to
determine cell viability as determined by two independent observers.
Cell death by apoptosis was determined by 7-amino actinomycin D (7AAD)
staining as previously described (14, 42). The effect of the
recombinant Fas-Fc protein (27) on induction of apoptosis by
DA-MEKK1 was determined by incubating the cells with 25 µg of
Fas-Fc/ml in the culture medium for the indicated time periods.
FasL expression.
DA-MEKK1 cells were grown under off
(tet+) or on (tet
) conditions for 24 h.
For comparison, Jurkat-tTA cells were either left untreated or
stimulated with 100 nM PMA plus 1 µg of ionomycin/ml for 12 h.
Immunostaining for FasL expression was performed by incubating the
cells with anti-FasL (NOK1) MAb, followed by fluorescein isothiocyanate
(FITC)-coupled anti-mouse immunoglobulin. The cells were analyzed by
flow cytometry, by using the Cell Quest program (Becton Dickinson).
 |
RESULTS |
Tetracycline-regulated expression of DA-MEKK1 induces
FasL-dependent apoptosis in Jurkat T cells.
We have established a
Jurkat cell line with stable, tetracycline-regulated DA-MEKK1
expression (Fig. 1) (15).
Cells grown in the presence of tetracycline (tet+) do not
express DA-MEKK1 (Fig. 1A, lane 1) and show basal levels of JNK
activity, which is inducible by treatment with PMA plus ionomycin (Fig.
1B, lanes 1 and 2). In contrast, in the absence of tetracycline
(tet
), an abundance of DA-MEKK1 is expressed (Fig. 1A,
lane 2), which resulted in an 18-fold increase in JNK activation over
unstimulated tet+ cells (Fig. 1B, lane 3). This JNK
activity is further enhanced by treatment with PMA plus ionomycin (Fig.
1B, lane 4). Compared to tet+ cells, 62% of cells die when
DA-MEKK1 is expressed for 72 h (Fig. 1C). This cell death is due
to apoptosis, as determined by 7AAD staining and demonstration of DNA
laddering (14). Moreover, addition of recombinant Fas-Fc
protein, which interferes in Fas-FasL binding, reduced the rate of
apoptosis in DA-MEKK1-expressing cells to near-background levels (Fig.
1C). As shown previously, we demonstrate by flow cytometry de novo FasL
expression in DA-MEKK1-expressing cells as well as in cells activated
by PMA plus ionomycin (Fig. 2). As
expected, protein expression at the cell surface is accompanied by an
increase in FasL message (data not shown) and correlates with FasL
reporter activity (14). Taken together, these data confirm
previous findings which indicate that prolonged MEKK1 activation leads
to the induction of apoptosis in a FasL-dependent manner
(14).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
Inducible expression of DA-MEKK1 in Jurkat cells leads
to constitutive JNK activation and induction of apoptosis. (A) Western
blot showing the inducible expression of DA-MEKK1 in stably transfected
Jurkat-tTA cells. Jurkat-tTA cells were transfected with 30 µg of
cDNA encoding DA-MEKK1 in the pUHD10.3 vector (lanes 1 and 2). Cells in
lane 3 were untransfected Jurkat-tTA cells. Following selection in 270 µg of hygromycin/ml for 4 weeks, the cells were grown in the presence
(+) or absence ( ) of 0.1 µg of tetracycline/ml for 24 h. Total
cell lysates from 5 × 106 cells were separated by
SDS-10% PAGE and transferred to an Immobilon-P membrane. The membrane
was overlaid with 0.1 µg of anti-MEKK1 antibody/ml, followed by
HRP-conjugated protein A, and was developed by ECL. (B) In vitro kinase
assay showing the constitutive activation of JNK by DA-MEKK1. The
transfected cells described above were either left untreated (lanes 1 and 3) or stimulated for 10 min with 100 nM PMA and 1 µg of
ionomycin/ml (P+I) at 37°C (lanes 2 and 4), and JNK activity was
measured as previously described (14). (C) Cell viability
assay in DA-MEKK1-expressing cells and the effect of Fas-Fc fusion
protein. DA-MEKK1 Jurkat cells were incubated in the presence or
absence of 30 µg of Fas-Fc/ml and grown under tet+ or
tet conditions for 72 h. Cell viability was measured
by trypan blue exclusion. Duplicate counts were performed by two
independent observers. We have previously shown that in these cells,
trypan blue uptake is accompanied by 7AAD uptake and DNA laddering
(14). Similar results were obtained in three separate
experiments.
|
|

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 2.
Immunostaining showing enhanced FasL expression in cells
expressing DA-MEKK1. DA-MEKK1 cells, grown under tet+ or
tet conditions for 36 h (A), were stained with
anti-FasL (NOK1) MAb, followed by FITC-coupled anti-mouse
immunoglobulin, and were analyzed by flow cytometry by using the Cell
Quest program (Becton Dickinson). For comparison, Jurkat-tTA cells were
either left untreated or stimulated with 100 nM PMA plus 1 µg of
ionomycin (Iono)/ml for 12 h (B) and analyzed as above.
|
|
Stress-induced FasL promoter activation is dependent on MEKK1
activity.
Under physiological and pathological conditions, the JNK
cascade is induced by a range of stress stimuli, including UV light,
-irradiation, DNA-damaging drugs, inflammatory cytokines, and protein synthesis inhibitors (21-23, 59). We have
previously shown that UVR,
-irradiation, and anisomycin induce FasL
expression in T lymphocytes (14). Transient transfection of
a FasL promoter-reporter construct (FasL
486), containing 486 bp
immediately upstream of the transcriptional start site (28),
into Jurkat DA-MEKK1 cells showed induction of luciferase activity in
tet
as compared to tet+ cells (Fig.
3A). Further treatment of
tet+ cells with PMA plus ionomycin, a potent stimulus for
JNK in T cells, also leads to the induction of FasL reporter activity
(Fig. 3A). These results show that constitutively active MEKK1 induces transcriptional activation of the FasL promoter in Jurkat T cells.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
Regulation of the transcriptional activation of the FasL
promoter by DA- and DN-MEKK1. (A) Luciferase assay showing the
regulation of the FasL promoter by DA-MEKK1. DA-MEKK1 cells,
transiently transfected with 30 µg of FasL-486 luciferase construct,
were grown in the presence [Tet(+)] or absence [Tet( )] of 0.1 µg of tetracycline/ml for 24 h. Cells were left unstimulated or
were treated with 100 nM PMA plus 1 µg of ionomycin (Iono)/ml for
8 h. The cells were lysed, and 100 µg of cell lysates was
analyzed for luciferase activity. The fold increase in luciferase
activity was calculated over the value for unstimulated
tet+ cells, which amounted to 6,576 relative light units.
These data are representative of four experiments. (B) Luciferase
activity showing the effect of DN-MEKK1 on the activation of the FasL
promoter by stress stimuli. Jurkat tTA cells were transiently
cotransfected with 30 µg of FasL-486 luciferase and 20 µg of
DN-MEKK1 subcloned into the pUHD10.3 vector. The cells were grown in
the presence or absence of 0.1 µg of tetracycline/ml for 24 h
and were stimulated with 200 J of UVR/m2 or 3,300 rads
of -irradiation in the presence of 30 µM
Z-Val-Ala-Asp(OMe)-CH2F (Z-VAD). The cells were lysed
8 h later and analyzed for luciferase activity. Fold increase in
luciferase activity was calculated over the value for unstimulated
tet+ cells, which amounted to 7,380 relative light units.
These data are representative of three experiments.
|
|
As previously mentioned, UVR and

-irradiation induce activation of
the FasL promoter-reporter (
14). In order to determine
whether MEKK1 plays a role in this induction, we used transient,
tetracycline-regulated expression of DN-MEKK1 in Jurkat-tTA cells
(Fig.
3B). In the absence of DN-MEKK1 expression, UVR and

-irradiation
induced a 4.8- or 5.2-fold increase in FasL promoter-luciferase
activity (Fig.
3B). Expression of DN-MEKK1 markedly reduced the
UVR-
and

-irradiation-induced FasL reporter activity (Fig.
3B).
These
results show that the transcriptional activation of the
FasL promoter
by environmental stress stimuli is dependent on
kinases upstream of
JNK.
Sequential deletion of the FasL promoter maps the MEKK1 response
element downstream of bp
335.
To identify the MEKK1-responsive
site in the FasL promoter, we generated serial 5' deletion mutants of
the
486-bp promoter-reporter and inserted these into the Luc-Link
reporter (Fig. 4A). We compared the
promoter-reporter activity of these mutants to that of the wild-type
promoter by transient transfection into Jurkat DA-MEKK1 cells (Fig.
4B). Compared to tet+ cells, DA-MEKK1 induced almost
identical increases in luciferase activity in the FasL
486,
420,
369, and
353 reporters (Fig. 4B). In contrast, DA-MEKK1 failed to
stimulate promoter-reporter activity in constructs downstream of bp
335. The loss in reporter gene activity in promoter constructs
shorter than 335 bp was not due to differences in transfection
efficiency, since this was corrected for by cotransfection of a
-galactosidase-expressing vector. Similar results were obtained with
PMA-ionomycin stimulation (data not shown), suggesting that the MEKK1
response element is located downstream of bp
335.

View larger version (19K):
[in this window]
[in a new window]

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 4.
The MEKK1 response element maps downstream of position
335 in the FasL promoter. (A) Schematic representation of the FasL
promoter-reporter constructs showing the MEKK1- and NF-AT-responsive
elements (RE) in the 486-bp promoter. Serial 5' deletion mutants were
generated as described in Materials and Methods. (B) Comparison of
luciferase activity in the FasL promoter deletion mutants. DA-MEKK1
cells were transiently transfected with 30 µg of the 486-bp FasL
luciferase construct or its 5' deletion mutants. Luciferase activity
was determined as described above. The fold increase in luciferase
activity was calculated over the value of tet+ cells, which
amounted to 10,142 relative light units. These data are representative
of three experiments.
|
|
The JNK cascade induces mobility shift complexes with an
oligonucleotide corresponding to positions
336 to
318 of the FasL
promoter.
The precipitous decline of FasL promoter-reporter
activity with promoter truncations 3' of
335 suggests that this base
pair may be at or in close proximity to the actual MEKK1 response
element. We therefore constructed an oligonucleotide corresponding to
bp
336 to
318 of the FasL promoter to probe for a MEKK1 response element. This sequence (5'-TTGGGTAGCACAGCGA-3') does not
contain homology to a recognized AP-1 binding site. In an EMSA, nuclear extracts from resting Jurkat cells displayed constitutive binding of
two shift bands to this probe (Fig. 5A,
lane 8). Both bands were abolished in the presence of a molar excess of
unlabeled oligonucleotide, indicating binding specificity (Fig. 5A,
lane 14). PMA plus ionomycin increased the abundance of both shift complexes (Fig. 5A, lane 9), which are larger than the shift complexes obtained with a consensus AP-1 oligonucleotide (Fig. 5A, lane 2).

View larger version (78K):
[in this window]
[in a new window]

View larger version (50K):
[in this window]
[in a new window]

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 5.
MEKK1 activation induces a mobility shift complex with
an oligonucleotide corresponding to positions 336 to 318 of the
FasL promoter. (A) EMSA showing the association of c-Jun and ATF2 with
the MEKK1-responsive site of the FasL promoter. A total of 5 × 106 Jurkat-tTA cells were either left untreated or
stimulated with 100 nM PMA plus 1 µg of ionomycin (Iono)/ml for
3 h. Nuclear extracts (10 µg) were incubated in buffer or
pretreated with 0.5 µg of anti-pan-Jun (lane 3), anti-c-Jun (lanes 4 and 11), anti-pan-Fos (lanes 5 and 12), or anti-ATF2 (lane 13)
polyclonal antibodies or with nonimmune serum (NIS) (lanes 6 and 10)
for 40 min. EMSA was performed by using a 32P-labeled AP-1
oligonucleotide (lanes 1 through 7) or the oligonucleotide
corresponding to positions 336 to 318 from the start site of the
FasL promoter (lanes 8 through 14). The DNA-binding complexes were
separated by 4.5% acrylamide gel electrophoresis. The gel was dried
and visualized by autoradiography. (B) EMSA showing that DA-MEKK1
induces DNA shift complexes with the MEKK1-responsive site of the FasL
promoter. A total of 5 × 106 Jurkat-tTA cells, stably
transfected with DA-MEKK1, were grown in the presence (+) or absence
( ) of tetracycline for 24 h. The cells were either left
untreated or stimulated with 100 nM PMA plus 1 µg of ionomycin
(Iono)/ml for 3 h. Nuclear extracts (10 µg) were incubated with
2 ng of 32P-labeled AP-1 oligonucleotide (lanes 1 through
5) or the oligonucleotide corresponding to the JNK response element
(lanes 6 through 10). The DNA-binding complexes were analyzed as
described above. (C) EMSA showing the effects of anti-c-Jun and
anti-ATF2 on DA-MEKK1-induced shift complexes. EMSA was conducted by
using the MEKK1-responsive oligonucleotide together with nuclear
extracts from DA-MEKK1-expressing Jurkat cells as described for panel
B. Anti-c-Jun, anti-ATF2, and anti-Fos antibodies were incubated
together with the nuclear extracts as described above for panel A.
|
|
Based on the role of the JNK cascade in regulating the expression and
transcriptional activation of AP-1 proteins (
57,
58),
we
asked whether the

336-to-

318 response element in the FasL
promoter
associates with members of the AP-1 protein family. Nuclear
extracts
from cells treated with PMA plus ionomycin were preincubated
with
antibodies to c-Jun, ATF2, or pan-Fos and were analyzed by
EMSA (Fig.
5A). While treatment with anti-c-Jun and anti-ATF2
interfered with the
binding of both complexes to the FasL oligonucleotide
(Fig.
5A, lanes
11 and 13), anti-pan-Fos had no effect on the
protein-DNA interaction
(Fig.
5A, lane 12). This indicates the
presence of c-Jun and ATF2 but
not Fos proteins in the FasL oligonucleotide
complexes. In contrast,
supershift analysis using the consensus
AP-1 probe revealed the
presence of both c-Jun and Fos family
proteins in the complex (Fig.
5A,
lanes 3 to 5). This suggests
that although both complexes contain AP-1
proteins, there are
differences in the makeup of these transcription
factors.
To determine whether MEKK1 induces similar shift complexes, nuclear
extracts were prepared from DA-MEKK1 expressing Jurkat
cells and
incubated together with the

336-to-

318 probe (Fig.
5B, lanes 6 to
10). DA-MEKK1 expression induced two gel shift
complexes, both of which
specifically associate with the FasL
probe (Fig.
5B, lane 8) and are
competed with a 50-fold excess
of unlabeled probe (Fig.
5B, lane 10).
Compared to tet
+ cells, there was increased abundance of
both complexes in tet

cells (Fig.
5B, lanes 6 and 8).
Similarly, UVR and

-irradiation
induced two shift complexes with the

336-to-

318 probe, indicating
that relevant stress stimuli target
the same response element
(data not shown).
In order to determine which AP-1 proteins are induced to bind to the

336-to-

318 probe by DA-MEKK1, we used the same antibodies
shown in
Fig.
5A to conduct supershift analysis using nuclear
extracts from
DA-MEKK1-expressing cells. The data showed decreased
complex formation
in the presence of anti-c-Jun and anti-ATF2
antibodies but did not show
an effect for anti-pan-Fos antiserum
(Fig.
5C). This is in agreement
with the findings in Fig.
5A.
The MEKK1 response element in the FasL promoter functions
independently to drive transcription in JNK-activated cells.
We
next addressed whether the
336-to-
318 binding site in the FasL
promoter can act independently as a MEKK1 response element. We inserted
a triplicate repeat of the
336-to-
318 binding site upstream of a
luciferase reporter. This construct was transiently transfected into
DA-MEKK1 cells, and luciferase activity was measured in
DA-MEKK1-expressing versus non-DA-MEKK1-expressing cells (Fig. 6A). In control nonexpressing
tet+ cells, treatment with PMA plus ionomycin, induced a
4.6-fold increase in the activity of the triplicated MEKK1 response
element reporter (Fig. 6A), similar to results seen with the 486-bp
promoter. Further, the expression of DA-MEKK1 results in a 6.6-fold
induction of the activity of the triplicated reporter luciferase, again similar to results seen with the full-length FasL reporter (Fig. 6A).
UVR and
-irradiation also induced activation of the triplicated MEKK1 response element, and this response could be inhibited by DN-MEKK1 (Table 1). These results
indicate that, analogous to the intact FasL promoter, the triplicated
individual response element at
336 to
318 is regulated through a
pathway involving MEKK1.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
The response element between positions 336 and 318
is critical for MEKK1-mediated FasL promoter activity. (A) Luciferase
assay showing the effect of the DA-MEKK1 on the transcriptional
activation of the MEKK1-responsive element. DA-MEKK1 cells were
transiently transfected with 30 µg of luciferase constructs
representing the 486-bp FasL promoter or the triplicated 336-to- 318
site. The cells were grown in the presence or absence of 0.1 µg of
tetracycline/ml for 24 h. Cells were either left unstimulated or
treated with 100 nM PMA plus 1 µg of ionomycin (Iono)/ml for 8 h. The cells were lysed and analyzed for luciferase activity as for
Fig. 3. The fold increase in luciferase activity was calculated based
on the value for tet+ cells. Transfection efficiency was
monitored by cotransfection of a -galactosidase-encoding plasmid
(CMV- -Gal). These data are representative of three experiments. (B)
Luciferase assay showing the regulation of the FasL promoter by the
MEKK1 response element. DA-MEKK1 cells were transiently transfected
with 30 µg of the wild-type FasL-486 reporter or the
FasL 336/ 318 construct carrying a mutant MEKK1-responsive
element. The cells were grown in the presence or absence of 0.1 µg of
tetracycline/ml for 24 h, lysed, and analyzed for luciferase
activity. The fold increase in luciferase activity was calculated based
on the value for tet+ cells.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Luciferase reporter assay showing activation of the
triplicated MEKK1 response element by UVR
and -irradiationa
|
|
An important question is whether the above MEKK1-inducible element
plays a critical role in the activation of the 486-bp FasL
promoter. We
mutagenized that site in the full-length promoter
sequence and
transfected that mutant reporter gene into Jurkat
DA-MEKK1 cells (Fig.
6B). Our data show that while DA-MEKK1 induced
a 5.2-fold increase in
the transcriptional activation of the wild-type
FasL promoter, only a
1.3-fold increase could be achieved in cells
transfected with the
mutant promoter (Fig.
6B). Similarly, where
stress stimuli such as UVR
and

-irradiation were used, the respective
9.8- and 9.2-fold
increases in FasL promoter activity were abrogated
by mutation of the
MEKK1-responsive element (Table
2). Taken
together, our results suggest that the MEKK1-inducible site located
between

336 and

318 plays a critical role in stress-induced
transcriptional activation of the FasL promoter.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Luciferase reporter assay showing lack of activation of
the mutant FasL promoter by UVR
and -irradiationa
|
|
Distinct response elements mediate the activation of the FasL
promoter by the TCR and stress stimuli.
We have previously shown
that ligation of the TCR induces the transcriptional activation of the
FasL promoter by inducing the activation of the distal NF-AT site in
that promoter (28). Mutation of the distal NF-AT site
prevents the activation of the FasL promoter by anti-CD3 (Fig.
7), confirming our previous findings (28). Transient transfection of the FasL promoter construct lacking the distal NF-AT site (FasL
NFAT) into DA-MEKK1 cells showed
that, in contrast to TCR-mediated activation, mutation of the distal
NF-AT site did not interfere in the transcriptional activation of the
FasL promoter by DA-MEKK1 (Fig. 7). In fact, the response of the
FasL
NFAT-Luc reporter was increased compared to that of the
wild-type promoter. Whether this reflects involvement of a repressor or
a positional effect changing transcription factor interactions with the
polymerase II initiation complex is unknown at present.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 7.
Distinct response elements mediate the activation of the
FasL promoter by the TCR and DA-MEKK1. DA-MEKK1 cells, transiently
transfected with 30 µg of FasL 486, FasL 336/ 318, or
FasL NFAT luciferase constructs, were grown in the presence or
absence of 0.1 µg of tetracycline/ml for 24 h. The cells were
either left unstimulated or treated with 10 µg of anti-CD3 MAb/ml for
8 h. The cells were lysed and analyzed for luciferase activity.
The fold increase in luciferase activity was calculated based on the
value for tet+ cells. Transfection efficiency was monitored
by cotransfection of a -galactosidase-encoding plasmid. Similar
results were obtained in two experiments.
|
|
In the reverse experiment, we investigated the effect of TCR ligation
on the FasL promoter construct containing a mutant MEKK1
site
(FasL


336/

318). As shown in Fig.
6, mutation of the

338-to-

318
site abrogated the responsiveness of the FasL promoter
to DA-MEKK1
(Fig.
7). In contrast, anti-CD3 stimulation resulted in
similar
responses in wild-type FasL and mutant FasL promoters (Fig.
7).
These results indicate that TCR ligation and the JNK cascade induce
the
expression of FasL by utilizing distinct response elements
in the FasL
promoter.
DN mutants of c-Jun and ATF2 interfere in the JNK-mediated
activation of the FasL promoter.
Data shown in Fig. 5A suggest
that the MEKK1-inducible site associates with c-Jun and ATF2 proteins.
To determine whether these transcription factors play an essential role
in the transcriptional activation of the FasL promoter, we used mutant
c-Jun (Jun 63/73) and mutant ATF2 (ATF2 69/71) (20, 41)
constructs to determine their effects on the FasL promoter. While in
the presence of wild-type c-Jun, DA-MEKK1 induced an eightfold increase
in FasL promoter activity, mutant c-Jun (Fig.
8A) and mutant ATF2 (Fig. 8B) abrogated reporter activity by 75% (Fig. 8A) and 54% (Fig. 8B), respectively. Similarly, the mutant constructs reduced responsiveness to PMA plus
ionomycin by 75% (Fig. 8A) and 50% (Fig. 8B), respectively, in
tet+ and tet
cells. Moreover, mutant c-Jun
(Jun 63/73) and mutant ATF2 (ATF2 69/71) exerted inhibitory effects on
the individual response element used as a triplicate repeat of the
JNK-inducible site in a luciferase vector (Fig. 8C and D). The
proportionally smaller effect of DN c-Jun on the individual response
element (Fig. 8C) compared to the wild-type promoter (Fig. 8A) may be
due to differences in the level of mutant c-Jun expression in these
experiments. Taken together, these data show that c-Jun and ATF2 play a
critical role in the transcriptional activation of the FasL promoter
and the MEKK-inducible site in that promoter. Since in the above
experiments we used c-Jun and ATF2 mutants which lack consensus serine
residues required for transcriptional activation by JNK (20,
41), our data suggest the involvement of JNK in the events
downstream of MEKK1. Further confirmation of that notion was sought by
looking at the effect of a dominant interfering mutant of the JNK
kinase, SEK1, on transcriptional activation of the wild-type FasL-Luc reporter by UVR and PMA plus ionomycin. Our data demonstrate 6.5- and
5.2-fold stimulation of FasL-Luc by UVR and PMA plus ionomycin, respectively; in the presence of DN-SEK1, these responses were limited
to 2.6- and 2.0-fold increases, respectively. This supports a role for
JNK in the activation of the FasL promoter.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 8.
Involvement of c-Jun and ATF2 in the MEKK1-mediated
activation of the FasL promoter. (A and C) Luciferase assay showing the
effect of mutant c-Jun on the transcriptional activation of the FasL
promoter (A) and the triplicated MEKK1-responsive element (C). DA-MEKK1
cells were transiently transfected with 30 µg of FasL 486 or
triplicated JNK response element reporter constructs in the presence of
20 µg of either wild-type (WT) or mutant (63/73) c-Jun. The
experiment was performed as described for Fig. 3. The intersample
variation in transfection efficiency was adjusted by using CMV- -Gal
cotransfection. (B and D) Luciferase assay showing the effect of mutant
ATF2 on the transcriptional activation of the FasL promoter (B) and the
triplicated MEKK1-responsive element (D). DA-MEKK1 cells were
transiently transfected with 30 µg of FasL 486 or triplicated JNK
response element reporter constructs in the presence of 20 µg of
either wild-type (WT) or mutant (69/71) ATF2. The experiment was
performed as described above.
|
|
 |
DISCUSSION |
In this paper, we show that induction of FasL gene expression by
environmental stress stimuli is dependent on MEKK1 activation. Using
inducible DA-MEKK1 expression in Jurkat cells, we demonstrate the
presence of a specific MEKK1- regulated element at positions
338
to
316 of the FasL promoter. Mutation of that response element abrogated MEKK1-mediated FasL promoter activation and interfered in
stress-induced induction of this promoter. The effect of MEKK1 on the
FasL promoter is mediated by c-Jun and ATF2, which associate with and
transcriptionally activate the MEKK1 response element. Transfection of
interfering c-Jun and ATF2 mutants, which lack the consensus JNK
phosphorylation sites, abrogated the transcriptional activation of the
FasL promoter in parallel with the triplicated JNK response element.
Together, these data indicate that MEKK1 and downstream targets of the
JNK cascade play a role in committing lymphocytes to apoptosis by
inducing FasL expression via a novel response element in the promoter
of that gene.
Previous studies have linked JNK activation with apoptosis. While the
role of the JNK cascade in apoptosis has been controversial, our
studies suggest that the role of MEKK1 is the commitment of T cells to
apoptosis rather than the actual delivery of the death signal. In favor
of this hypothesis are the findings that neither DN-MEKK1 nor DN-SEK1
interferes in Fas-induced apoptosis (18, 55), while DA-MEKK1
is able to induce apoptosis (14, 26, 58). Moreover,
DA-MEKK1-mediated apoptosis can be inhibited by interfering with
Fas-FasL interactions (Fig. 1). We propose, therefore, that FasL
expression represents a mechanism through which MEKK1 commits T cells
to apoptosis. The kinetics of MEKK1 activation appear to be important
in this process, since prolonged, but not transient, activation leads
to induction of apoptosis (7, 8, 14). The kinetics of MEKK1
activation may set a threshold which influences the decision of T cells
to die when they are irreversibly damaged by environmental stress.
Instead of directly inducing apoptosis, the JNK cascade regulates the expression of FasL, which subsequently delivers the death signal through Fas (Fig. 3). The JNK cascade may therefore function as a
fail-safe mechanism that induces cell death when ligands for death
effector domain receptors are not readily available. Another ligand
which may play a role in MEKK1-induced apoptosis is the cytokine which
binds to TNFR1, namely, TNF-
. In this regard, DA-MEKK1 has been
demonstrated to induce TNF-
secretion in mast cells in parallel with
transcriptional activation of the TNF-
promoter (24).
TNF-
secretion may serve as an alternative or complementary
mechanism which contributes to stress-induced apoptosis (11). The use of one or both mechanisms may differ from
tissue to tissue or stimulus to stimulus. For instance, UVR has been shown to induce FasL expression in T cells and keratinocytes while inducing TNF-
in keratinocytes but not in peripheral-blood T lymphocytes (30, 51). It is important to mention that UVR- and
-irradiation-induced apoptosis may involve mechanisms other than
FasL expression, since Fas-Fc protein, which interferes in Fas-FasL
binding, only partially inhibits induction of cell death by these
stress stimuli (14). Possible mechanisms include expression of additional apoptotic receptors or their ligands, e.g., TNF-
, as
well as activation of further signaling pathways, e.g., p38 mitogen-activated protein kinase (MAPK) and NF-
B kinases. In this
regard, putative AP-1 and NF-
B response elements have been defined
in the FasL promoter >900 bp upstream of the start site (27a). The latter study also confirmed the involvement of
MEKK1 in a stress-induced apoptosis in Jurkat cells with a
tetracycline-regulated vector system (27a). Our data differ
from the findings of this study, however, in that we could not show
significant JNK activation in Jurkat cells by the genotoxic agents,
etoposide and tenoposide, used in that study (27a). We do
not understand the reason for these differences. It is also important
to consider the dose of UVR and
-irradiation in FasL-mediated
apoptosis, because a decrease in the dose of
-irradiation from 3,300 to 1,500 rads induced apoptosis which could be blocked >40% by Fas-Fc
protein (14). Moreover, the dose of Fas-Fc protein may be
important in demonstrating the role of FasL, since a higher dose of
Fas-Fc protein has been demonstrated to inhibit UVR-induced apoptosis
in Jurkat cells by >50% (27a). While we clearly need to
learn more about UVR- and
-irradiation-induced apoptosis pathways,
our published data demonstrate that these stress stimuli do induce FasL
expression, which contributes to apoptosis (14). As a
cautionary note, we also want to emphasize that our study does not rule
out a role for the JNK cascade in the execution of apoptosis in
nonlymphoid cells. Indeed, recent studies have shown that the Fas
binding protein Daxx plays a role in apoptosis in fibroblasts through activation of the JNK cascade (59). The mechanism of action of JNK in the apoptotic machinery of these cells needs to be
elucidated.
Our data suggest that the mechanism by which MEKK1 regulates the FasL
promoter is through the transcriptional activation of c-Jun and ATF2,
which interact with the
336-to-
318 element (Fig. 5). This is in
keeping with the well-characterized effect of JNK on the
transcriptional activation and expression of AP-1 proteins (34,
47, 56, 57). The transcriptional activation of c-Jun is dependent
on JNK-induced phosphorylation of serine residues, S63 and S73, in its
N-terminal domain (12, 47). Moreover, expression of c-Jun is
dependent on transcriptional activation of a modified AP-1 site in the
c-Jun promoter known as the cyclic AMP response element binding protein
(CREB)/ATF2 site, which binds to a c-Jun-ATF2 heterodimer (34,
47). It is interesting, therefore, that ATF2 transcriptional
activation is also dependent on JNK phosphorylation (20).
Further evidence for the involvement of JNK in the events downstream of
MEKK1 was provided by the finding that DN-SEK1 (JNK kinase) could
reduce the activation of the wild-type FasL promoter by 60 and 62%,
respectively, upon stimulation with UVR and PMA plus ionomycin. Our
finding that the MEKK1 response element in the FasL promoter interacts
with c-Jun and ATF2 (Fig. 5) prompted us to compare the
336-to-
318
sequence of the FasL promoter to AP-1 and AP-1-like sequences which are
known to play a role in the transcriptional activation of genes in the
immune system (Table 3). As demonstrated
in Table 3, our sequence did not match any of the AP-1, AP-1-like, or
CREB/ATF2 sequences published to date (10, 16, 32, 35, 36,
53). However, this sequence did show short homologous sequences
(ACA or GGTA) which appear in some modified AP-1 sites. Neither a BLAST
homology search nor use of the TESS database revealed any sequences in
the mammalian genome which exactly match the FasL promoter response
element. We suggest, therefore, that our sequence represents a novel
CREB/AP-1 binding site. This notion is further supported by the fact
that mutant c-Jun and ATF2, lacking JNK phosphorylation sites, prevent the transcriptional activation of the FasL promoter and the triplicated JNK response element in that promoter (Fig. 8).
In light of the multitude of stimuli which induce FasL expression, it
is likely that, in addition to the MEKK1 response element located at
336 to
318, other response elements in the FasL promoter may play a
role in the regulation of that gene. For instance, ligation of the TCR
induces the apoptosis of T lymphocytes by activation-induced cell
death, a process dependent on FasL expression (52, 54). We
have shown that this response is mediated through an NF-AT site at
position
276 of the FasL promoter (28). As expected from
an NF-AT-dependent response, transcriptional activation of the FasL
promoter by the TCR occurred via a Ca2+-dependent pathway
inhibitable by cyclosporin A (28). We have previously shown
that mutation of this NF-AT response element decreases the
responsiveness of the FasL promoter to TCR ligation (28).
Although the distal NF-AT site is critical for FasL expression following TCR ligation, mutation of that site in the FasL promoter had
no inhibitory effect on the transcriptional activation of the mutant
promoter by DA-MEKK1 (data not shown). This suggests that TCR
engagement and environmental stress utilize different mechanisms for
the induction of the FasL promoter. Stress stimuli function by inducing
the prolonged activation of the JNK cascade (7, 8),
resulting in the transcriptional activation of c-Jun and ATF2 (56,
57). In contrast, ligation of the TCR without CD28 costimulation
fails to induce JNK activation (15, 49). Therefore, while
TCR functions by inducing a Ca2+-dependent pathway
resulting in NF-AT activation, stress stimuli induce FasL expression by
way of the JNK cascade. Although TCR and stress stimuli induce FasL
gene expression by two different signaling pathways, these processes
are not mutually exclusive. The JNK cascade may synergize with
TCR-mediated events in order to remove damaged or excess cells. This
may be especially true in cases of inflammatory diseases.
Taken together, our data support a model in which prolonged MEKK1
activation by stress stimuli commit the cells to undergo apoptosis by
inducing the expression of FasL on the cell surface. This method of
cell death seems to play an essential role in the immune system, as
demonstrated by the inability of MRL-lpr/lpr mice to eliminate excess
lymphocytes in response to irradiation (9, 43). Although the
role of the JNK cascade in the induction of apoptosis is not limited to
lymphoid cells, the extent of cell death mediated by the JNK cascade
may be cell type specific. While T lymphocytes respond to prolonged JNK
activation by expressing FasL and undergoing apoptosis, other cell
types, such as small-cell lung cancer cells and prostate cells, may
require alternative means of inducing cell death (3).
 |
ACKNOWLEDGMENTS |
This work was supported by United States Public Health Service
grants AG14763, AG14992, and AI52735. A.N. is supported by the Southern
California Chapter of the Arthritis Foundation. G.A.K. is also
supported by the Arthritis Foundation. K.M.L. is supported by the
University of Iowa Medical Scientist Training Program, NIH grant
T326M07337.
M. Faris and K. M. Latinis contributed equally to this study.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: UCLA School of
Medicine, Department of Medicine, 52-175 CHS, 10833 Le Conte Ave., Los Angeles, CA 90095. Phone: (310) 825-6620. Fax: (310) 206-8107. E-mail:
anel{at}med1.medsch.ucla.edu.
 |
REFERENCES |
| 1.
|
Boldin, M. P.,
T. M. Goncharov,
Y. Y. Goltsev, and D. Wallach.
1996.
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.
Cell
85:803-815[Medline].
|
| 2.
|
Brenner, C.,
T. Hirsch,
P. X. Petit,
M. Geuskens, and G. Kroemer.
1997.
A cytofluorometric assay of nuclear apoptosis induced in a cell-free system: application to ceramide-induced apoptosis.
Exp. Cell Res.
236:397-403[Medline].
|
| 3.
|
Butterfield, L.,
B. Storey,
L. Maas, and L. E. Heasley.
1997.
c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation.
J. Biol. Chem.
272:10110-10116[Abstract/Free Full Text].
|
| 4.
|
Cahill, M. A.,
M. E. Peter,
F. C. Kischkel,
A. M. Chinnaiyan,
V. M. Dixit,
P. H. Krammer, and A. Nordheim.
1996.
CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases.
Oncogene
13:2087-2096[Medline].
|
| 5.
|
Calnan, B. J.,
S. Szychowski,
F. K. Chan,
D. Cado, and A. Winoto.
1995.
A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection.
Immunity
3:273-282[Medline].
|
| 6.
|
Castro, J. E.,
J. A. Listman,
B. A. Jacobson,
Y. Wang,
P. A. Lopez,
S. Ju,
P. W. Finn, and D. L. Perkins.
1996.
Fas modulation of apoptosis during negative selection of thymocytes.
Immunity
5:617-627[Medline].
|
| 7.
|
Chen, Y. R.,
C. F. Meyer, and T.-H. Tan.
1996.
Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis.
J. Biol. Chem.
271:631[Abstract/Free Full Text].
|
| 8.
|
Chen, Y. R.,
X. Wang,
D. Templeton,
R. J. Davis, and T.-H. Tan.
1996.
The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation.
J. Biol. Chem.
271:31929-31936[Abstract/Free Full Text].
|
| 9.
|
Cheng, J.,
C. Liu,
P. Yang,
T. Zhou, and J. D. Mountz.
1997.
Increased lymphocyte apoptosis in Fas ligand transgenic mice.
J. Immunol.
15:674-684.
|
| 10.
|
Cippitelli, M.,
A. Sica,
V. Viggiano,
J. Ye,
P. Ghosh,
M. J. Birrer, and H. A. Young.
1995.
Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun.
J. Biol. Chem.
270:12548-12556[Abstract/Free Full Text].
|
| 11.
|
de Kossodo, S.,
P. D. Cruz, Jr.,
I. Dougherty,
P. Thompson,
M. Silva-Valdez, and B. Beutler.
1995.
Expression of the tumor necrosis factor gene by dermal fibroblasts in response to ultraviolet irradiation or lipopolysaccharide.
J. Investig. Dermatol.
104:318-322[Medline].
|
| 12.
|
Derijard, B.,
M. Hibi,
I. H. Wu,
T. Barrett,
B. Su,
T. Deng,
M. Karin, and R. J. Davis.
1994.
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.
Cell
76:1025-1037[Medline].
|
| 13.
|
Enari, M.,
R. V. Talanian,
W. W. Wong, and S. Nagata.
1996.
Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis.
Nature
380:723-726[Medline].
|
| 14.
|
Faris, M.,
N. Kokot,
K. Latinis,
S. Kasibhatla,
D. R. Green,
G. A. Koretzky, and A. Nel.
1998.
The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression.
J. Immunol.
160:134-144[Abstract/Free Full Text].
|
| 15.
|
Faris, M.,
N. Kokot,
L. Lee, and A. E. Nel.
1996.
Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells. Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation.
J. Biol. Chem.
271:27366-27373[Abstract/Free Full Text].
|
| 16.
|
Fraser, J. D.,
B. A. Irving,
G. R. Crabtree, and A. Weiss.
1991.
Regulation of interleukin-2 gene enhancer activity by the T-cell accessory molecule CD28.
Science
251:313-316[Abstract/Free Full Text].
|
| 17.
|
Gajewski, T. F., and C. B. Thompson.
1996.
Apoptosis meets signal transduction: elimination of a BAD influence.
Cell
87:589-592[Medline]. (Comment.)
|
| 18.
|
Goillot, E.,
J. Raingeaud,
A. Ranger,
R. I. Tepper,
R. J. Davis,
E. Harlow, and I. Sanchez.
1997.
Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway.
Proc. Natl. Acad. Sci. USA
94:3302-3307[Abstract/Free Full Text].
|
| 19.
|
Gossen, M.,
S. Freundlieb,
G. Bender,
G. Muler,
W. Hillen, and H. Bujard.
1995.
Transcriptional activation by tetracyclines in mammalian cells.
Science
68:1766-1769.
|
| 20.
|
Gupta, S.,
D. Campbell,
B. Derijard, and R. J. Davis.
1995.
Transcription factor ATF2 regulation by the JNK signal transduction pathway.
Science
267:389-393[Abstract/Free Full Text].
|
| 21.
|
Haimovitz-Friedman, A.,
C. C. Kan,
D. Ehleiter,
R. S. Persaud,
M. McLoughlin,
Z. Fuks, and R. N. Kolesnick.
1994.
Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis.
J. Exp. Med.
180:525-535[Abstract/Free Full Text].
|
| 22.
|
Hsu, H.,
J. Huang,
H. B. Shu,
V. Baichwal, and D. V. Goeddel.
1996.
TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex.
Immunity
4:387-396[Medline].
|
| 23.
|
Hsu, H.,
H. B. Shu,
M. G. Pan, and D. V. Goeddel.
1996.
TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways.
Cell
84:299-308[Medline].
|
| 24.
|
Ishizuka, T.,
N. Terada,
P. Gerwins,
E. Hamelmann,
A. Oshiba,
G. R. Fanger,
G. L. Johnson, and E. W. Gelfand.
1997.
Mast cell tumor necrosis factor alpha production is regulated by MEK kinases.
Proc. Natl. Acad. Sci. USA
94:6358-6363[Abstract/Free Full Text].
|
| 25.
|
Jamieson, C.,
P. G. McCaffrey,
A. Rao, and R. Sen.
1991.
Physiologic activation of T-cells via the T-cell receptors induces NF-kappa-B.
J. Immunol.
147:416-420[Abstract].
|
| 26.
|
Johnson, N. L.,
A. M. Gardner,
K. M. Diener,
C. A. Lange-Carter,
J. Gleavy,
M. B. Jarpe,
A. Minden,
M. Karin,
L. I. Zon, and G. L. Johnson.
1996.
Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death.
J. Biol. Chem.
271:3229-3237[Abstract/Free Full Text].
|
| 27.
|
Ju, S. T.,
D. J. Panka,
H. Cui,
R. Ettinger,
M. el-Khatib,
D. H. Sherr,
B. Z. Stanger, and A. Marshak-Rothstein.
1995.
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.
Nature
373:444-448[Medline].
|
| 27a.
|
Kasibhatla, S.,
T. Brunner,
L. Genestier,
F. Echeverria,
A. Mahboubi, and D. R. Green.
1998.
DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF- B and AP-1.
Mol. Cell
1:543-551[Medline].
|
| 28.
|
Latinis, K. M.,
L. L. Carr,
E. J. Peterson,
L. A. Norian,
S. L. Eliason, and G. A. Koretzky.
1997.
Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events.
J. Immunol.
158:4602-4611[Abstract].
|
| 29.
|
Lenczowski, J. M.,
L. Dominguez,
A. M. Eder,
L. B. King,
C. M. Zacharchuk, and J. D. Ashwell.
1997.
Lack of a role for Jun kinase and AP-1 in Fas-induced apoptosis.
Mol. Cell. Biol.
17:170-181[Abstract].
|
| 30.
|
Leverkus, M.,
M. Yaar, and B. A. Gilchrest.
1997.
Fas/Fas ligand interaction contributes to UV-induced apoptosis in human keratinocytes.
Exp. Cell Res.
232:255-262[Medline].
|
| 31.
|
Liu, Z. G.,
H. Hsu,
D. V. Goeddel, and M. Karin.
1996.
Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappa B activation prevents cell death.
Cell
87:565-5676[Medline].
|
| 32.
|
Mattila, P. S.,
K. S. Ullman,
S. Fierling,
E. A. Emmel, et al.
1990.
The actions of cyclosporin-A and FK506 suggest a novel step in the activation of T-lymphocytes.
EMBO
9:4425-4433[Medline].
|
| 33.
|
Minden, A.,
A. Lin,
M. McMahon,
C. Lange-Carter,
B. Derijard,
R. J. Davis,
G. L. Johnson, and M. Karin.
1994.
Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK.
Science
266:1719-1723[Abstract/Free Full Text].
|
| 34.
|
Minden, A.,
A. Lin,
T. Smeal,
B. Derijard,
M. Cobb,
R. Davis, and M. Karin.
1994.
c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases.
Mol. Cell. Biol.
14:6683-6688[Abstract/Free Full Text].
|
| 35.
|
Moriuchi, H.,
M. Moriuchi, and A. S. Fauci.
1997.
Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection.
J. Immunol.
158:3483-3491[Abstract].
|
| 36.
|
Muzio, M.,
A. M. Chinnaiyan,
F. C. Kischkel,
K. O'Rourke,
A. Shevchenko,
J. Ni,
C. Scaffidi,
J. D. Bretz,
M. Zhang,
R. Gentz,
M. Mann,
P. Krammer,
M. E. Peter, and V. M. Dixit.
1996.
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex.
Cell
85:817-827[Medline].
|
| 37.
|
Nagata, S.
1997.
Apoptosis by death factor.
Cell
88:355-365[Medline].
|
| 38.
|
Nishina, H.,
K. D. Fischer,
L. Radvanyi,
A. Shahinian,
R. Hakem,
E. A. Rubie,
A. Bernstein,
T. W. Mak,
J. R. Woodgett, and J. M. Penninger.
1997.
Stress-signalling kinase Sek1 protects thymocytes from apoptosis mediated by CD95 and CD3.
Nature
385:350-353[Medline].
|
| 39.
|
Okamoto, S. I.,
N. Mukaida,
K. Yasumoto,
N. Rice,
Y. Ishikawa,
H. Horiguchi,
S. Murakami, and K. Matsushima.
1994.
The interleukin-8 AP-1 and B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization.
J. Biol. Chem.
269:8582-8589[Abstract/Free Full Text].
|
| 40.
|
Pandey, S., and E. Wang.
1995.
Cells en route to apoptosis are characterized by the upregulation of c-fos, c-myc, c-jun, cdc2, and RB phosphorylation, resembling events of early cell-cycle traverse.
J. Cell. Biochem.
58:135-150[Medline].
|
| 41.
|
Petrak, D.,
S. A. Memon,
M. J. Birrer,
J. D. Ashwell, and C. M. Zacharchuk.
1994.
Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription.
J. Immunol.
153:2046-2051[Abstract].
|
| 42.
|
Philpott, N. J.,
A. J. C. Turner,
J. Scopes,
M. Westby,
J. C. W. Marsh,
E. C. Gordon-Smith,
A. G. Dalgleish, and F. M. Gibson.
1996.
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum application compared with other techniques.
Blood
87:2244-2251[Abstract/Free Full Text].
|
| 43.
|
Reap, E. A.,
K. Roof,
K. Maynor,
M. Borrero,
J. Booker, and P. L. Cohen.
1997.
Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions.
Proc. Natl. Acad. Sci. USA
94:5750-5755[Abstract/Free Full Text].
|
| 44.
|
Rooney, J. W.,
T. Hoey, and L. H. Glimcher.
1995.
Coordinate and cooperative roles for NF-AT and AP-1 in the regulation of the murine IL-4 gene.
Immunity
2:473-483[Medline].
|
| 45.
|
Russell, H.
1995.
Activation-induced death of mature T cells in the regulation of immune responses.
Curr. Opin. Immunol.
7:382-388[Medline].
|
| 46.
|
Salvesen, G. S., and V. M. Dixit.
1997.
Caspases: intracellular signaling by proteolysis.
Cell
91:443-446[Medline].
|
| 47.
|
Sanchez, I.,
R. T. Hughes,
B. J. Mayer,
K. Yee,
J. R. Woodgett,
J. Avruch,
J. M. Kyriakis, and L. I. Zon.
1994.
Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun.
Nature
372:794-798[Medline].
|
| 48.
|
Srinivasula, S. M.,
M. Ahmad,
S. Ottilie,
F. Bullrich,
S. Banks,
Y. Wang,
T. Fernandes-Alnemri,
C. M. Croce,
G. Litwack,
K. J. Tomaselli,
R. C. Armstrong, and E. S. Alnemri.
1997.
FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis.
J. Biol. Chem.
272:18542-18545[Abstract/Free Full Text].
|
| 49.
|
Su, B.,
E. Jacinto,
M. Hibi,
T. Kallunki,
M. Karin, and Y. Ben-Neriah.
1994.
JNK is involved in signal integration during costimulation of T lymphocytes.
Cell
77:727-736[Medline].
|
| 50.
|
Susin, S. A.,
N. Zamzami,
N. Larochette,
B. Dallaporta,
I. Marzo,
C. Brenner,
T. Hirsch,
P. X. Petit,
M. Geuskens, and G. Kroemer.
1997.
A cytofluorometric assay of nuclear apoptosis induced in a cell-free system: application to ceramide-induced apoptosis.
Exp. Cell Res.
236:397-403.
|
| 51.
|
Teunissen, M. B.,
R. M. Sylva-Steenland, and J. D. Bos.
1993.
Effect of low-dose ultraviolet-B radiation on the function of human T lymphocytes in vitro.
Clin. Exp. Immunol.
94:208-213[Medline].
|
| 52.
|
Thompson, C. B.
1995.
Apoptosis in the pathogenesis and treatment of disease.
Science
267:1456-1462[Abstract/Free Full Text].
|
| 53.
|
Tsai, E. Y.,
J. Jain,
P. A. Pesavento,
A. Rao, and A. E. Goldfeld.
1996.
Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp.
Mol. Cell. Biol.
16:459-467[Abstract].
|
| 54.
|
Van Parijs, L.,
A. Ibraghimov, and A. K. Abbas.
1996.
The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance.
Immunity
4:321-328[Medline].
|
| 55.
|
Verheij, M.,
R. Bose,
X. H. Lin,
B. Yao,
W. D. Jarvis,
S. Grant,
M. J. Birrer,
E. Szabo,
L. I. Zon,
J. M. Kyriakis,
A. Halmovitz-Friedman,
Z. Fuks, and R. N. Kolesnick.
1996.
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.
Nature
380:75-79[Medline].
|
| 56.
|
Westwick, J. K.,
A. D. Cox,
C. J. Der,
M. H. Cobb,
M. Hibi,
M. Karin, and D. A. Brenner.
1994.
Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.
Proc. Natl. Acad. Sci. USA
91:6030-6034[Abstract/Free Full Text].
|
| 57.
|
Whitmarsh, A. J., and R. J. Davis.
1996.
Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways.
J. Mol. Med.
74:589-607[Medline].
|
| 58.
|
Xia, Z.,
M. Dickens,
J. Raingeaud,
R. J. Davis, and M. Greenberg.
1995.
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.
Science
270:1326-1331[Abstract/Free Full Text].
|
| 59.
|
Yang, X.,
R. Khosravi-Far,
H. Y. Chang, and D. Baltimore.
1997.
Daxx, a novel Fas-binding protein that activates JNK and apoptosis.
Cell
89:1067-1076[Medline].
|
Molecular and Cellular Biology, September 1998, p. 5414-5424, Vol. 18, No. 9
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yuan, Z., Gong, S., Luo, J., Zheng, Z., Song, B., Ma, S., Guo, J., Hu, C., Thiel, G., Vinson, C., Hu, C.-D., Wang, Y., Li, M.
(2009). Opposing Roles for ATF2 and c-Fos in c-Jun-Mediated Neuronal Apoptosis. Mol. Cell. Biol.
29: 2431-2442
[Abstract]
[Full Text]
-
Gaitanaki, C., Mastri, M., Aggeli, I.-K. S., Beis, I.
(2008). Differential roles of p38-MAPK and JNKs in mediating early protection or apoptosis in the hyperthermic perfused amphibian heart. J. Exp. Biol.
211: 2524-2532
[Abstract]
[Full Text]
-
Pan, J., Wang, G., Yang, H.-Q., Hong, Z., Xiao, Q., Ren, R.-J., Zhou, H.-Y., Bai, L., Chen, S.-D.
(2007). K252a Prevents Nigral Dopaminergic Cell Death Induced by 6-Hydroxydopamine through Inhibition of Both Mixed-Lineage Kinase 3/c-Jun NH2-Terminal Kinase 3 (JNK3) and Apoptosis-Inducing Kinase 1/JNK3 Signaling Pathways. Mol. Pharmacol.
72: 1607-1618
[Abstract]
[Full Text]
-
Christmann, M., Tomicic, M. T., Aasland, D., Kaina, B.
(2007). A role for UV-light-induced c-Fos: stimulation of nucleotide excision repair and protection against sustained JNK activation and apoptosis. Carcinogenesis
28: 183-190
[Abstract]
[Full Text]
-
Zhong, C.-Y., Zhou, Y. M., Joad, J. P., Pinkerton, K. E.
(2006). Environmental Tobacco Smoke Suppresses Nuclear Factor-{kappa}B Signaling to Increase Apoptosis in Infant Monkey Lungs. Am. J. Respir. Crit. Care Med.
174: 428-436
[Abstract]
[Full Text]
-
Liu, X.-M., Pei, D.-S., Guan, Q.-H., Sun, Y.-F., Wang, X.-T., Zhang, Q.-X., Zhang, G.-Y.
(2006). Neuroprotection of Tat-GluR6-9c against Neuronal Death Induced by Kainate in Rat Hippocampus via Nuclear and Non-nuclear Pathways. J. Biol. Chem.
281: 17432-17445
[Abstract]
[Full Text]
-
Castellano, R., Vire, B., Pion, M., Quivy, V., Olive, D., Hirsch, I., Van Lint, C., Collette, Y.
(2006). Active Transcription of the Human FASL/CD95L/TNFSF6 Promoter Region in T Lymphocytes Involves Chromatin Remodeling: ROLE OF DNA METHYLATION AND PROTEIN ACETYLATION SUGGEST DISTINCT MECHANISMS OF TRANSCRIPTIONAL REPRESSION. J. Biol. Chem.
281: 14719-14728
[Abstract]
[Full Text]
-
Pei, D.-S., Wang, X.-T., Liu, Y., Sun, Y.-F., Guan, Q.-H., Wang, W., Yan, J.-Z., Zong, Y.-Y., Xu, T.-L., Zhang, G.-Y.
(2006). Neuroprotection against ischaemic brain injury by a GluR6-9c peptide containing the TAT protein transduction sequence. Brain
129: 465-479
[Abstract]
[Full Text]
-
Ben-David, H., Sela, M., Mozes, E.
(2005). Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis. Proc. Natl. Acad. Sci. USA
102: 2028-2033
[Abstract]
[Full Text]
-
Aikin, R., Maysinger, D., Rosenberg, L.
(2004). Cross-Talk between Phosphatidylinositol 3-Kinase/AKT and c-Jun NH2-Terminal Kinase Mediates Survival of Isolated Human Islets. Endocrinology
145: 4522-4531
[Abstract]
[Full Text]
-
Shrivastava, P., Pantano, C., Watkin, R., McElhinney, B., Guala, A., Poynter, M. L., Persinger, R. L., Budd, R., Janssen-Heininger, Y.
(2004). Reactive Nitrogen Species-Induced Cell Death Requires Fas-Dependent Activation of c-Jun N-Terminal Kinase. Mol. Cell. Biol.
24: 6763-6772
[Abstract]
[Full Text]
-
Kanda, H., Miura, M.
(2004). Regulatory Roles of JNK in Programmed Cell Death. J Biochem
136: 1-6
[Abstract]
[Full Text]
-
Crist, S. A., Griffith, T. S., Ratliff, T. L.
(2003). Structure/Function Analysis of the Murine CD95L Promoter Reveals the Identification of a Novel Transcriptional Repressor and Functional CD28 Response Element. J. Biol. Chem.
278: 35950-35958
[Abstract]
[Full Text]
-
Cenci, S., Toraldo, G., Weitzmann, M. N., Roggia, C., Gao, Y., Qian, W. P., Sierra, O., Pacifici, R.
(2003). Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-{gamma}-induced class II transactivator. Proc. Natl. Acad. Sci. USA
100: 10405-10410
[Abstract]
[Full Text]
-
Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., Claret, F. X.
(2003). Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells. J. Biol. Chem.
278: 19245-19256
[Abstract]
[Full Text]
-
Luo, J., Sun, Y., Lin, H., Qian, Y., Li, Z., Leonard, S. S., Huang, C., Shi, X.
(2003). Activation of JNK by Vanadate Induces a Fas-associated Death Domain (FADD)-dependent Death of Cerebellar Granule Progenitors in Vitro. J. Biol. Chem.
278: 4542-4551
[Abstract]
[Full Text]
-
Waetzig, V., Herdegen, T.
(2003). A Single c-Jun N-terminal Kinase Isoform (JNK3-p54) Is an Effector in Both Neuronal Differentiation and Cell Death. J. Biol. Chem.
278: 567-572
[Abstract]
[Full Text]
-
Lei, K., Nimnual, A., Zong, W.-X., Kennedy, N. J., Flavell, R. A., Thompson, C. B., Bar-Sagi, D., Davis, R. J.
(2002). The Bax Subfamily of Bcl2-Related Proteins Is Essential for Apoptotic Signal Transduction by c-Jun NH2-Terminal Kinase. Mol. Cell. Biol.
22: 4929-4942
[Abstract]
[Full Text]
-
Muscarella, D. E., Bloom, S. E.
(2002). Differential Activation of the c-Jun N-Terminal Kinase Pathway in Arsenite-Induced Apoptosis and Sensitization of Chemically Resistant Compared to Susceptible B-Lymphoma Cell Lines. Toxicol Sci
68: 82-92
[Abstract]
[Full Text]
-
Gabai, V. L., Sherman, M. Y.
(2002). Molecular Biology of Thermoregulation: Invited Review: Interplay between molecular chaperones and signaling pathways in survival of heat shock. J. Appl. Physiol.
92: 1743-1748
[Abstract]
[Full Text]
-
Aoki, H., Kang, P. M., Hampe, J., Yoshimura, K., Noma, T., Matsuzaki, M., Izumo, S.
(2002). Direct Activation of Mitochondrial Apoptosis Machinery by c-Jun N-terminal Kinase in Adult Cardiac Myocytes. J. Biol. Chem.
277: 10244-10250
[Abstract]
[Full Text]
-
Schlesinger, T. K., Bonvin, C., Jarpe, M. B., Fanger, G. R., Cardinaux, J.-R., Johnson, G. L., Widmann, C.
(2002). Apoptosis Stimulated by the 91-kDa Caspase Cleavage MEKK1 Fragment Requires Translocation to Soluble Cellular Compartments. J. Biol. Chem.
277: 10283-10291
[Abstract]
[Full Text]
-
Gibson, E. M., Henson, E. S., Villanueva, J., Gibson, S. B.
(2002). MEK Kinase 1 Induces Mitochondrial Permeability Transition Leading to Apoptosis Independent of Cytochrome c Release. J. Biol. Chem.
277: 10573-10580
[Abstract]
[Full Text]
-
Miller, A. T., Berg, L. J.
(2002). Defective Fas Ligand Expression and Activation-Induced Cell Death in the Absence of IL-2-Inducible T Cell Kinase. J. Immunol.
168: 2163-2172
[Abstract]
[Full Text]
-
Ishibashi, N., Prokopenko, O., Reuhl, K. R., Mirochnitchenko, O.
(2002). Inflammatory Response and Glutathione Peroxidase in a Model of Stroke. J. Immunol.
168: 1926-1933
[Abstract]
[Full Text]
-
Suhara, T., Kim, H.-S., Kirshenbaum, L. A., Walsh, K.
(2002). Suppression of Akt Signaling Induces Fas Ligand Expression: Involvement of Caspase and Jun Kinase Activation in Akt-Mediated Fas Ligand Regulation. Mol. Cell. Biol.
22: 680-691
[Abstract]
[Full Text]
-
Devadas, S., Zaritskaya, L., Rhee, S. G., Oberley, L., Williams, M. S.
(2002). Discrete Generation of Superoxide and Hydrogen Peroxide by T Cell Receptor Stimulation: Selective Regulation of Mitogen-Activated Protein Kinase Activation and Fas Ligand Expression. JEM
195: 59-70
[Abstract]
[Full Text]
-
Ortiz, M. A., Lopez-Hernandez, F. J., Bayon, Y., Pfahl, M., Piedrafita, F. J.
(2001). Retinoid-related Molecules Induce Cytochrome c Release and Apoptosis through Activation of c-Jun NH2-Terminal Kinase/p38 Mitogen-activated Protein Kinases. Cancer Res.
61: 8504-8512
[Abstract]
[Full Text]
-
Kwan, R., Burnside, J., Kurosaki, T., Cheng, G.
(2001). MEKK1 Is Essential for DT40 Cell Apoptosis in Response to Microtubule Disruption. Mol. Cell. Biol.
21: 7183-7190
[Abstract]
[Full Text]
-
Jackle, T., Hasel, C., Melzner, I., Bruderlein, S., Jehle, P. M., Moller, P.
(2001). Sustained hyposmotic stress induces cell death: apoptosis by defeat. Am. J. Physiol. Cell Physiol.
281: C1716-C1726
[Abstract]
[Full Text]
-
Herr, I., Debatin, K.-M.
(2001). Cellular stress response and apoptosis in cancer therapy. Blood
98: 2603-2614
[Abstract]
[Full Text]
-
Morishima, Y., Gotoh, Y., Zieg, J., Barrett, T., Takano, H., Flavell, R., Davis, R. J., Shirasaki, Y., Greenberg, M. E.
(2001). {beta}-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand. J. Neurosci.
21: 7551-7560
[Abstract]
[Full Text]
-
Dzialo-Hatton, R., Milbrandt, J., Hockett, R. D. Jr., Weaver, C. T.
(2001). Differential Expression of Fas Ligand in Th1 and Th2 Cells Is Regulated by Early Growth Response Gene and NF-AT Family Members. J. Immunol.
166: 4534-4542
[Abstract]
[Full Text]
-
Garcia, C.L., Carloni, M., de la Pena, N.P., Fonti, E., Palitti, F.
(2001). Detection of DNA primary damage by premature chromosome condensation in human peripheral blood lymphocytes treated with methyl methanesulfonate. Mutagenesis
16: 121-125
[Abstract]
[Full Text]
-
Gourley, T. S., Chang, C.-H.
(2001). Cutting Edge: The Class II Transactivator Prevents Activation-Induced Cell Death by Inhibiting Fas Ligand Gene Expression. J. Immunol.
166: 2917-2921
[Abstract]
[Full Text]
-
Reimold, A. M., Kim, J., Finberg, R., Glimcher, L. H.
(2001). Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int Immunol
13: 241-248
[Abstract]
[Full Text]
-
Eichhorst, S. T., Müller, M., Li-Weber, M., Schulze-Bergkamen, H., Angel, P., Krammer, P. H.
(2000). A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs. Mol. Cell. Biol.
20: 7826-7837
[Abstract]
[Full Text]
-
NAPOLI, C., QUEHENBERGER, O., DE NIGRIS, F., ABETE, P., GLASS, C. K., PALINSKI, W.
(2000). Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J.
14: 1996-2007
[Abstract]
[Full Text]
-
Fine, A., Janssen-Heininger, Y., Soultanakis, R. P., Swisher, S. G., Uhal, B. D.
(2000). Apoptosis in lung pathophysiology. Am. J. Physiol. Lung Cell. Mol. Physiol.
279: L423-L427
[Abstract]
[Full Text]
-
Khoshnan, A., Tindell, C., Laux, I., Bae, D., Bennett, B., Nel, A. E.
(2000). The NF-{kappa}B Cascade Is Important in Bcl-xL Expression and for the Anti-Apoptotic Effects of the CD28 Receptor in Primary Human CD4+ Lymphocytes. J. Immunol.
165: 1743-1754
[Abstract]
[Full Text]
-
Chow, W. A., Fang, J. J., Yee, J.-K.
(2000). The IFN Regulatory Factor Family Participates in Regulation of Fas Ligand Gene Expression in T Cells. J. Immunol.
164: 3512-3518
[Abstract]
[Full Text]
-
Zhang, J., Gao, J.-X., Salojin, K., Shao, Q., Grattan, M., Meagher, C., Laird, D. W., Delovitch, T. L.
(2000). Regulation of FAS Ligand Expression during Activation-Induced Cell Death in T Cells by p38 Mitogen-Activated Protein Kinase and C-Jun Nh2-Terminal Kinase. JEM
191: 1017-1030
[Abstract]
[Full Text]
-
Matsui, K., Xiao, S., Fine, A., Ju, S.-T.
(2000). Role of Activator Protein-1 in TCR-Mediated Regulation of the Murine fasl Promoter. J. Immunol.
164: 3002-3008
[Abstract]
[Full Text]
-
Kolbus, A., Herr, I., Schreiber, M., Debatin, K.-M., Wagner, E. F., Angel, P.
(2000). c-Jun-Dependent CD95-L Expression Is a Rate-Limiting Step in the Induction of Apoptosis by Alkylating Agents. Mol. Cell. Biol.
20: 575-582
[Abstract]
[Full Text]
-
Li, X. R., Chong, A. S.-F., Wu, J., Roebuck, K. A., Kumar, A., Parrillo, J. E., Rapp, U. R., Kimberly, R. P., Williams, J. W., Xu, X.
(1999). Transcriptional Regulation of Fas Gene Expression by GA-binding Protein and AP-1 in T Cell Antigen Receptor{middle dot}CD3 Complex-stimulated T Cells. J. Biol. Chem.
274: 35203-35210
[Abstract]
[Full Text]
-
Villalba, M., Kasibhatla, S., Genestier, L., Mahboubi, A., Green, D. R., Altman, A.
(1999). Protein Kinase C{theta} Cooperates with Calcineurin to Induce Fas Ligand Expression During Activation-Induced T Cell Death. J. Immunol.
163: 5813-5819
[Abstract]
[Full Text]
-
Hiura, T. S., Kaszubowski, M. P., Li, N., Nel, A. E.
(1999). Chemicals in Diesel Exhaust Particles Generate Reactive Oxygen Radicals and Induce Apoptosis in Macrophages. J. Immunol.
163: 5582-5591
[Abstract]
[Full Text]
-
Noguchi, K., Kitanaka, C., Yamana, H., Kokubu, A., Mochizuki, T., Kuchino, Y.
(1999). Regulation of c-Myc through Phosphorylation at Ser-62 and Ser-71 by c-Jun N-Terminal Kinase. J. Biol. Chem.
274: 32580-32587
[Abstract]
[Full Text]
-
Hsu, S.-C., Gavrilin, M. A., Tsai, M.-H., Han, J., Lai, M.-Z.
(1999). p38 Mitogen-activated Protein Kinase Is Involved in Fas Ligand Expression. J. Biol. Chem.
274: 25769-25776
[Abstract]
[Full Text]
-
Gibson, S., Tu, S., Oyer, R., Anderson, S. M., Johnson, G. L.
(1999). Epidermal Growth Factor Protects Epithelial Cells against Fas-induced Apoptosis. REQUIREMENT FOR Akt ACTIVATION. J. Biol. Chem.
274: 17612-17618
[Abstract]
[Full Text]
-
Ivanov, V. N., Ronai, Z.'e.
(1999). Down-regulation of Tumor Necrosis Factor alpha Expression by Activating Transcription Factor 2 Increases UVC-induced Apoptosis of Late-stage Melanoma Cells. J. Biol. Chem.
274: 14079-14089
[Abstract]
[Full Text]
-
van den Brink, M. R. M., Kapeller, R., Pratt, J. C., Chang, J.-H., Burakoff, S. J.
(1999). The Extracellular Signal-regulated Kinase Pathway Is Required for Activation-induced Cell Death of T Cells. J. Biol. Chem.
274: 11178-11185
[Abstract]
[Full Text]
-
Kempiak, S. J., Hiura, T. S., Nel, A. E.
(1999). The Jun Kinase Cascade Is Responsible for Activating the CD28 Response Element of the IL-2 Promoter: Proof of Cross-Talk with the I{kappa}B Kinase Cascade. J. Immunol.
162: 3176-3187
[Abstract]
[Full Text]
-
Rivera-Walsh, I., Cvijic, M. E., Xiao, G., Sun, S.-C.
(2000). The NF-kappa B Signaling Pathway Is Not Required for Fas Ligand Gene Induction but Mediates Protection from Activation-induced Cell Death. J. Biol. Chem.
275: 25222-25230
[Abstract]
[Full Text]
-
Achenbach, T. V., Muller, R., Slater, E. P.
(2000). Bcl-2 Independence of Flavopiridol-induced Apoptosis. MITOCHONDRIAL DEPOLARIZATION IN THE ABSENCE OF CYTOCHROME c RELEASE. J. Biol. Chem.
275: 32089-32097
[Abstract]
[Full Text]
-
Thangaraju, M., Kaufmann, S. H., Couch, F. J.
(2000). BRCA1 Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines. J. Biol. Chem.
275: 33487-33496
[Abstract]
[Full Text]
-
Li, M., Kondo, T., Zhao, Q.-L., Li, F.-J., Tanabe, K., Arai, Y., Zhou, Z.-C., Kasuya, M.
(2000). Apoptosis Induced by Cadmium in Human Lymphoma U937 Cells through Ca2+-calpain and Caspase-Mitochondria- dependent Pathways. J. Biol. Chem.
275: 39702-39709
[Abstract]
[Full Text]
-
Chen, Y., Lai, M.-Z.
(2001). c-Jun NH2-terminal Kinase Activation Leads to a FADD-dependent but Fas Ligand-independent Cell Death in Jurkat T Cells. J. Biol. Chem.
276: 8350-8357
[Abstract]
[Full Text]
-
Kavurma, M. M., Santiago, F. S., Bonfoco, E., Khachigian, L. M.
(2001). Sp1 Phosphorylation Regulates Apoptosis via Extracellular FasL-Fas Engagement. J. Biol. Chem.
276: 4964-4971
[Abstract]
[Full Text]